What is the clinical evidence from this study?

Study design: Case-Control. Population: Sporadic Atrial Fibrillation (n=728). Intervention: TBX20 variations vs. Healthy subjects without AF history. Primary outcome: Presence of TBX20 variations.

What does this research mean for the field?

Haplo-insufficient TBX20 variations predispose individuals to sporadic atrial fibrillation by disrupting the transactivation of key cardiovascular genes such as KCNH2 and NPPA. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the prevalence, spectrum, and functional consequences of TBX20 gene variations in patients with sporadic atrial fibrillation.

September 5, 2026BiomedicinesOpen Access

Novel TBX20 Variations Susceptible to Sporadic Atrial Fibrillation

View Full Paper

Ask AI

Bookmark

Why the study?

Are TBX20 variations associated with susceptibility to sporadic atrial fibrillation?

Population

352 individuals with sporadic atrial fibrillation and 376 healthy subjects without AF history

Comparison

Sanger sequencing of TBX20 and functional… vs 376 healthy subjects without AF history

Design

Case-control

Key result

Two novel heterozygous truncating TBX20 variations were detected in 0.57% of patients with sporadic atrial fibrillation, but were absent in healthy controls.

Authors

ZXZhen-Yu Xu DZDao-Liang Zhang XQXing‐Biao Qiu

Discussion

Member takes

Overview

Rare TBX20 truncating variants may predispose to sporadic AF; extends genetic spectrum but leaves open clinical relevance pending replication.

Key Points

To investigate the prevalence, spectrum, and functional consequences of TBX20 gene variations in patients with sporadic atrial fibrillation.
Prospectively recruited 352 individuals with sporadic atrial fibrillation and 376 healthy controls without a history of atrial fibrillation.
Performed Sanger sequencing of the TBX20 gene in all 728 participants.
Assessed the functional impact of identified variants on target promoters (KCNH2, NPPA) and synergistic activation with NKX2.5 using dual-reporter gene assays.
Identified two novel heterozygous truncating TBX20 variants, p.(Ser242*) and p.(Lys276*), in 2 of 352 sporadic AF cases (prevalence of ~0.57%), while neither variant was found across 752 control chromosomes.
Functional assays demonstrated that both Ser242* and Lys276* variants completely lost transactivation capacity on KCNH2 and NPPA promoters.
Both variants abolished the synergistic transactivation of the NPPA promoter normally mediated by TBX20 in combination with NKX2.5.

Study Design

Type

Case-Control (n=728)

Structured PICO

Are TBX20 variations associated with susceptibility to sporadic atrial fibrillation?

Population

728 individuals, comprising 352 with sporadic atrial fibrillation and 376 healthy controls, prospectively recruited for genetic analysis.

Exposure

Sanger sequencing of TBX20 and functional measurement by dual-reporter gene analysis

Comparator

376 healthy subjects without AF history

Outcome

Detection of TBX20 variations and their functional impacts on transactivation of KCNH2 and NPPAsurrogate

Main Result

Absolute Event Rate: 0.57% vs 0%

Novel haplo-insufficient TBX20 variations are identified as genetic defects predisposing to sporadic atrial fibrillation, expanding the genetic spectrum of the disease.

Cite This Study

Xu et al. (2026) conducted a case-control in Sporadic Atrial Fibrillation (n=728). TBX20 variations vs. Healthy subjects without AF history was evaluated on Presence of TBX20 variations. Two novel heterozygous truncating TBX20 variations were detected in 0.57% of patients with sporadic atrial fibrillation, but were absent in healthy controls.

synapsesocial.com/papers/6a9bd4606b95aff0620ec090 https://doi.org/10.3390/biomedicines14091990

View Full Paper

Ask AI

Bookmark

September 5, 2026BiomedicinesOpen Access

Novel TBX20 Variations Susceptible to Sporadic Atrial Fibrillation

View Full Paper

Ask AI

Bookmark

Why the study?

Are TBX20 variations associated with susceptibility to sporadic atrial fibrillation?

Population

352 individuals with sporadic atrial fibrillation and 376 healthy subjects without AF history

Comparison

Sanger sequencing of TBX20 and functional… vs 376 healthy subjects without AF history

Design

Case-control

Key result

Two novel heterozygous truncating TBX20 variations were detected in 0.57% of patients with sporadic atrial fibrillation, but were absent in healthy controls.

Authors

ZXZhen-Yu Xu DZDao-Liang Zhang XQXing‐Biao Qiu

Discussion

Member takes

Overview

Rare TBX20 truncating variants may predispose to sporadic AF; extends genetic spectrum but leaves open clinical relevance pending replication.

Key Points

To investigate the prevalence, spectrum, and functional consequences of TBX20 gene variations in patients with sporadic atrial fibrillation.
Prospectively recruited 352 individuals with sporadic atrial fibrillation and 376 healthy controls without a history of atrial fibrillation.
Performed Sanger sequencing of the TBX20 gene in all 728 participants.
Assessed the functional impact of identified variants on target promoters (KCNH2, NPPA) and synergistic activation with NKX2.5 using dual-reporter gene assays.
Identified two novel heterozygous truncating TBX20 variants, p.(Ser242*) and p.(Lys276*), in 2 of 352 sporadic AF cases (prevalence of ~0.57%), while neither variant was found across 752 control chromosomes.
Functional assays demonstrated that both Ser242* and Lys276* variants completely lost transactivation capacity on KCNH2 and NPPA promoters.
Both variants abolished the synergistic transactivation of the NPPA promoter normally mediated by TBX20 in combination with NKX2.5.

Study Design

Type

Case-Control (n=728)

Structured PICO

Are TBX20 variations associated with susceptibility to sporadic atrial fibrillation?

Population

728 individuals, comprising 352 with sporadic atrial fibrillation and 376 healthy controls, prospectively recruited for genetic analysis.

Exposure

Sanger sequencing of TBX20 and functional measurement by dual-reporter gene analysis

Comparator

376 healthy subjects without AF history

Outcome

Detection of TBX20 variations and their functional impacts on transactivation of KCNH2 and NPPAsurrogate

Main Result

Absolute Event Rate: 0.57% vs 0%

Novel haplo-insufficient TBX20 variations are identified as genetic defects predisposing to sporadic atrial fibrillation, expanding the genetic spectrum of the disease.

Cite This Study

synapsesocial.com/papers/6a9bd4606b95aff0620ec090 https://doi.org/10.3390/biomedicines14091990

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark